The signaling connection between mitogen-activated protein kinases(MAPKs) and nuclear steroid receptors is complex and remains mostly unexplored. Here we report that stress-activated protein kinases p38 and JNK trans-activate nuclear steroid vitamin D receptor ( p38 and c-Jun NH 2 -terminal kinase (JNK) 1 are the major MAPK pathways, which, together with the extracellular signalregulated kinase (ERK) pathways, convert signals of various extracellular stimuli into expression of specific target genes through phosphorylation and activation of transcription factors (1-3). The ERK pathway, downstream of Ras, is predominantly activated by mitogenic stimuli, whereas the p38 and JNK pathways are preferentially stimulated by environmental stresses. Although biological consequence of p38 and JNK activation in many cases overlaps with that of the ERK (1-3), one of its principle functions is regulation of stress and the inflammatory response (4, 5). The mechanisms leading to the functional diversity and/or specificity of the cellular physiological outcome of MAPK signaling are largely unknown and may relate to regulation of their specific downstream target genes. Although the p38 and JNK pathways can regulate expression of many molecules (2, 6), only a few of the true target genes selectively responsive to these stress pathways have been identified.
p38 and c-Jun NH 2 -terminal kinase (JNK) 1 are the major MAPK pathways, which, together with the extracellular signalregulated kinase (ERK) pathways, convert signals of various extracellular stimuli into expression of specific target genes through phosphorylation and activation of transcription factors (1) (2) (3) . The ERK pathway, downstream of Ras, is predominantly activated by mitogenic stimuli, whereas the p38 and JNK pathways are preferentially stimulated by environmental stresses. Although biological consequence of p38 and JNK activation in many cases overlaps with that of the ERK (1-3), one of its principle functions is regulation of stress and the inflammatory response (4, 5) . The mechanisms leading to the functional diversity and/or specificity of the cellular physiological outcome of MAPK signaling are largely unknown and may relate to regulation of their specific downstream target genes. Although the p38 and JNK pathways can regulate expression of many molecules (2, 6) , only a few of the true target genes selectively responsive to these stress pathways have been identified.
The active form of vitamin D 3 , 1,25-dihydroxyvitamin D 3 , is a hormone with known activity in the regulation of calcium homeostasis, cell proliferation, and cell differentiation (7) . Vitamin D 3 binds to its nuclear steroid receptor (VDR), a transcription factor, which dimerizes with itself or other nuclear receptors such as retinoid X receptor (RXR) to regulate gene expression by specific vitamin D response elements (VDREs) through which vitamin D 3 exerts its biological effects (7, 8) . Vitamin D 3 is well known for its therapeutic activity against breast cancer, which in many cases requires the presence of functional VDR (9, 10) . Loss of VDR expression in human breast cancer cells is frequently associated with the resistance to vitamin D 3 -dependent growth inhibition (10) , whereas its up-regulation by different means increases the sensitivity in different systems (11) (12) (13) (14) . Alteration of VDR expression consequently emerges as an important approach for the regulation of vitamin D 3 activity in inhibition of cancer cell proliferation. The signaling mechanisms by which VDR is regulated, however, remain largely undiscovered.
The signaling connection between MAPK activation and nuclear steroid hormone receptors is complex. The classical model is that the steroid hormone, because of its hydrophobic property, diffuses across the cellular membrane and binds to its nuclear receptor to regulate target gene expression through specific steroid receptor-responsive regulatory elements in the target genes, unrelated to MAPK regulation (15, 16) . Recent experimental evidence suggests that there exist multiple interactions between the ERK-and JNK-MAPK pathways and the estrogen and progesterone steroid receptors at many levels (15, 16) . (i) The Ras-ERK pathway phosphorylates the estradiol/ estrogen receptor (ER) and increases its transcription activity (17) (18) (19) . (ii) In reverse, signaling through ER and progestins/ progesterone receptor (PR) stimulates the Ras/ERK activity (20 -22) . (iii) The JNK kinase MEKK1 stimulates the transcriptional activity of PR in a manner dependent (23) and independent of the ligand (24) . (iv) Interactions also can occur between transcription factors (c-Jun and c-Fos) activated by the MAPK pathways and the nuclear steroid receptors via direct binding (25, 26) . Although direct phosphorylation of ER and PR by MAPKs is involved in many of these processes, it remains unknown whether MAPKs can regulate steroid hormone receptor gene expression. Knowledge about transcriptional regulation of steroid receptor expression is critical for understanding steroid hormone effects. This is particularly important for VDR, because in many cell/tissue types the VDR level is limiting (7), and its concentration consequently largely determines the magnitude of the hormone-induced biological responses.
It has been postulated that the Ras/ERK suppresses vitamin D 3 /VDR signaling, because ras-transformed cells have lower levels of VDR expression than their normal counterparts (27) . Accordingly, ras-transformed keratinocytes are resistant to vitamin D 3 -induced growth inhibition in comparison with their normal counterparts (28, 29) . Consistent with this observation, activation of the Ras-ERK pathway by phorbol 12-myristate 13-acetate (30) , epidermal growth factor, and fibroblast growth factor (27) down-regulates VDR expression. Furthermore, elevated Ras/ERK activity was demonstrated to be correlated with the disruption of VDR/RXR heterodimer (31) . Because the Ras/ ERK and the p38 MAPK pathways frequently have an opposite role in many systems (32) (33) (34) , the inhibition of VDR activity by Ras may be either a direct consequence of Ras-ERK activation or the p38 pathway inactivation. Consequently, it may be reasoned that p38 kinase might stimulate VDR activity.
In this report we have tested the hypothesis that the stressactivated protein kinase p38 stimulates VDR and thereby increases VDR activity and vitamin D 3 -induced growth inhibition. By application of genetic as well as chemical stimuli, our results establish that the signaling through both the p38 and JNK integrated at c-Jun/AP-1 is not only sufficient but essential to trans-activate VDR. The VDR activation by this pathway was further shown to sensitize human breast cancer MCF-7 cells to vitamin D 3 -induced growth inhibition.
MATERIALS AND METHODS
cDNA Constructs and Expression Plasmids-Recombinant adenovirus vectors containing hemagglutinin-tagged MKK6 and MEK1 were constructed as described previously (35, 36) . Briefly, hemagglutinintagged active MKK6 and MEK1 were subcloned into the vector pAd/ RSV, and then were co-transfected with the adenovirus-packaging plasmid pJM17 into 293 cells. A control recombinant adenovirus lacking a cDNA insert was constructed using pAd/RSV and pJM17. High-titered stocks of the recombinant adenoviruses (ϳ1 ϫ 10 10 plaque-forming units/ml) were produced and purified at the Virus Core Facility of the Cleveland Clinic Foundation. Mouse VDR promoter (0.5 kb) was cloned and inserted into a pGL2 basic vector (Promega) in front of the luciferase gene as described previously (37, 38) . pCMV plasmids encoding constitutively active MEK (MEK/2E), constitutively active MEKK1 (truncated), pEBG-expressing GST-tagged ERK (p42MAPK), GSTtagged JNK (p54SAPK), and the bacterial expressing plasmid pGEX for GST-Jun were provided by Dennis Templeton (39, 40) and have been used previously in this laboratory (41) . A mammalian expressing plasmid pCMV-Tam67 (c-Jun lacking the trans-activation domain, residues 2-122) was originally provided by Michael Birrer (42) (43) (44) . pcDNA3-MKK6/E (MKK6) is a constitutively active mutant of MKK6 with Ser-207 and Thr-211 replaced by glutamic acid. This plasmid as well as the pCMV5 vectors containing FLAG-tagged wild type and kinase dead form of p38␣ (p38/AF) and pGEX for GST-ATF2 were kindly provided by Roger Davis (45) . A mammalian expression plasmid pcDNA3-containing cDNA for myc epitope-tagged MK2 was supplied by Matthias Gaestel (46) . pAC-CMV encoding activated Ha-Ras (Leu-61) was kindly provided by Christopher B. Newgard as described previously (41) . An AP-1 luciferase construct, which was generated by cloning three AP-1 repeats into a luciferase reporter gene containing a minimal Fos promoter, was kindly provided by Craig Hauser (47) .
Other Reagents-Minimum essential medium, L-glutamine, and antibiotics were supplied by Invitrogen. Fetal bovine serum was obtained from BioWhittaker. DNA was prepared using an Endofree kit from Qiagen. A DNA transfection kit (calcium phosphate) and a dual luciferase kit were purchased from Promega. SB203580 was purchased from Calbiochem. Glutathione agarose beads were from Sigma. Protein GSepharose 4B and protein A-Sepharose 4B beads were purchased from Zymed Laboratories. Goat anti-MKK6, rabbit anti-MEK1, rabbit anti-VDR, goat anti-JNK2, and rabbit antibodies against p38, c-Fos, c-Jun, and ATF2 (the ATF2 recombinant protein) were obtained from Santa Cruz Biotechnology. Anti-FLAG M2 affinity gel and MBP for ERK assay were bought from Sigma. Vitamin D 3 was provided by Hoffmann-La Roche. GST-Jun for JNK assay was purified with glutathione agarose beads (48) Cell Culture, Transfection, Infection, and Assay for Cell Proliferation-Human breast cancer cell lines MCF-7 and MDA-MB-468 were obtained from ATCC and maintained in minimal essential medium containing 10% fetal bovine serum and antibiotics at 37°C with 5% CO 2 . An MCF-7 subline stably expressing Tam67 (MCF/Tam) was generated by transfecting MCF-7 cells with equal amounts of pCMV-Tam and pcDNA3 (neomycin-resistant expression plasmid) using the Fu-GENE 6 kit (Invitrogen) followed by selection with 0.6 mg/ml G418 for one month (44) . The resistant clones were pooled, and early passages of these cells were used for experiments. Expression of the transfected c-Jun Tam67 was detected using a c-Jun antibody (sc-44-G, Santa Cruz Biotechnology) that recognizes the COOH-terminal DNA-binding region (residues 247-263) of c-Jun. For transient transfection, the protocol of calcium phosphate-mediated transfection from Promega followed. Cells were allowed to grow for 48 h in serum-free medium before being collected for various assays. For adenovirus infection, cells were typically plated for a day before and switched to serum-free medium the next day. Cells were incubated with adenovirus (50 plaque-forming units/cell) for 5 h and then further incubated for 24 (468) or 48 h (MCF-7) to allow expression of proteins of interest. For cell proliferation, cells were infected with the control virus or the adenovirus coding for MKK6 for 5 h in serum-free minimal essential medium in six-well plates as mentioned above. Following infection, cells were washed once with phosphate-buffered saline and fed with serum-free medium containing the vehicle or 0. (49) . After trypsinization, the amount of thymidine incorporated into cells was determined by scintillation counting using ScintiSafe TM Plus 50% (Fisher Scientific) in a Scintillation Counter (Beckman). The results of these proliferation studies and the following luciferase assay, Western blot analyses, Northern blot analyses, and kinase assays were analyzed with the Student's t test for the statistically significant difference.
Luciferase Assay and Site-directed Mutagenesis-Cells were transfected with calcium phosphate according to the Promega manual for 5 h (total 3 g of DNA per 2 ml/well in a six-well plate). By the end of the experiments (48 h after DNA removal), cells were washed with phosphate-buffered saline and collected in the lysis buffer. Luciferase activity of the promoter was assayed with a dual luciferase kit from Promega using pRL-TK (encoding Renilla luciferase) as a normalization control in a TD-20/20 Luminometer (Turner Designs). Mutations in the potential AP-1 binding site of mVDR-luc plasmid were performed with the QuikChange™ site-directed mutagenesis kit from Stratagene as instructed in the user manual. The sequences of the PCR primers were M1: FW, 5Ј-CTCAGGTACGGGTGCTACACCTGGGGGAGGCG-3Ј and REV, 5Ј-CGTAAACGCCTCCCCCAGGTGTAGCACCCGTACCTGAG-3Ј; M2: FW, 5Ј-CTCAGGTACGGGTGCTAGGCCTGGGGGAGGCG-3Ј and REV, 5Ј-CTGTAAACGCCTCCCCCAGGCCTAGCACCCGTACCT-GAG-3Ј. The size of the mutated plasmid was verified with restriction enzyme digestion analysis, and the correct sized plasmid was used for further confirmation by DNA sequencing for the desired mutations.
Western and Northern Blotting Analyses-For Western blot analyses, cells were lysed in modified radioimmune precipitation buffer (50 mM Tris, pH 7.5, 150 mM NaCl, 1% Nonidet P-40, 0.25% sodium deoxycholate, 1 mM EGTA, 10 mM NaF, 1 mM Na 3 VO 4 , 1 mM phenylmethylsulfonyl fluoride, and 1 g/ml aprotinin, leupeptin, and pepstatin). Protein concentration was determined by the DC Protein Assay kit (Bio-Rad). Typically, 50 g of protein was separated by SDS-PAGE, which was transferred to a nitrocellulose membrane for detection of the molecule of interest using ECL (Amersham Biosciences) as described previously (41) . For Northern blot, total RNA was prepared by TRIzol (Invitrogen). Human VDR cDNA in pCMV vector (kindly provided by Leonard Freedman (50)) was digested with ApaI/XbaI to generate a fragment as the probe. The probe was labeled with [ 32 P]dCTP using the High Prime kit (Roche Molecular Biochemicals) and purified with Quick Spin Columns (Roche Molecular Biochemicals). The Northern blots were standardized for equal application of RNA by comparing the UV fluorescence of the 18 S rRNA band.
Preparation of Nuclear Extract, Electrophoretical Mobility Shift Assay (EMSA)-Following infection or arsenite (ARS) treatment, about 1 ϫ 10
7 cells were lysed in 10 mM Tris, pH 8.0, containing 0.5% Nonidet P-40, 2 mM MgCl 2 , 5 mM KCl, and 1 mM phenylmethylsulfonyl fluoride on ice for 15 min after washing once with cold phosphate-buffered saline (51, 52) . Cells then were scraped down, and the pellets were resuspended in 100 l of nuclear lysis buffer (10 mM Tris, pH 8.0, 0.1% Nonidet P-40, 500 mM NaCl, 1 mM EDTA, and proteinase inhibitors (Cocktail, Roche Molecular Biochemicals). The mixture was incubated on ice for 30 min with vortexing every 5 min. Following spin, the supernatant was either stored at Ϫ80°C (normally used within 2 weeks) or used immediately for EMSA.
For EMSA, 5 g of nuclear protein was pre-incubated in DNA binding buffer (10 mM HEPES, pH 7.9, 60 mM KCl, 4% Ficoll, 1 mM dithiothreitol, 1 mM EDTA, 1 mg/ml of poly [d(I-C)] (Amersham Biosciences). In supershift assays, incubation was in the absence or presence of 1 g of respective antibody (Santa Cruz Biotechnology: rabbit anti-ATF2, cat. no. sc-187 X; rabbit anti c-Jun, cat. no. sc-44 X) for 15 min. The mixture was then incubated with ϳ10 5 cpm-labeled probe in the absence or presence of 50-fold cold oligos on ice for 30 min. The doublestranded oligonucleotides were obtained from Santa Cruz Biotechnology with the sequence as follows: AP-1 consensus oligonucleotide, 5Ј-CGC TTG ATG ACT CAG CCG GAA-3Ј; AP-1 mutant oligonucleotide, 5Ј-CGC TTG ATG ACT tgG CCG GAA-3Ј; VDRE consensus oligonucleotide (DR-3), 5Ј-AGC TTC AGG TCA AGG AGG TCA GAG AGC-3Ј.
The oligonucleotides were labeled with [ 32 P]ATP and T4 polynucleotide kinase for 45-60 min and purified by Qiaquick nucleotide remove kit (Qiagen). Following incubation, the mixture was subjected to a native 4.5% acrylamide gel in 0.5ϫ Tris borate/EDTA buffer. The gels then were dried and subjected to autoradiography.
Immunoprecipitation and Protein Kinase Assay-Cells were collected by trypsinization, and pellets were quick-frozen in liquid nitrogen after washing and spinning. The pellet either was stored at Ϫ80°C or was used immediately for protein preparation (resuspended in 100 l of the lysis buffer and incubated on ice for 30 min with vortexing for 30 s every 10 min). Protein (200 g) was incubated either with 30 l of 50% glutathione-agarose beads (Sigma) for GST-tagged ERK or JNK or with 20 l of anti-FLAG M2 affinity gel (Sigma) for FLAG-tagged p38 at 4°C in a rotating plate overnight. For endogenous JNK and p38 kinase assay, the protein was incubated with 1 g of polyclonal antibodies from Santa Cruz Biotechnology against JNK2 (sc-572) and p38 (sc-535) and with 30 l of protein A-Sepharose (Zymed Laboratories Inc.) at a volume of 300 l. All of the beads were washed four times with the lysis buffer before adding to the mixture.
The precipitates were washed twice with respective lysis buffer and twice with kinase binding buffer (20 mM HEPES pH 7.6, 50 mM NaCl, 0.05% Triton X-100, 0.1 mM EDTA, 2.5 mM MgCl 2 ). The kinase reaction was carried out at 30°C for 30 min in 25 l of kinase reaction buffer (20 mM HEPES pH 7.6, 20 mM MgCl 2 , 15 M ATP, 20 mM ␤-glycerolphosphate, 20 mM p-nitrophenyl phosphate, 0.5 mM Na 3 VO 4 , 2 mM dithiothreitol) as described previously (41, 49) . [␥-
32 P]ATP (5 Ci) and 1 g of substrate protein were used for each sample. Substrates for the kinase reactions were MBP for ERK, GST-Jun for JNK, and ATF-2 for p38. Following a 30-min reaction at 30°C, an equal volume of 2ϫ Laemmli buffer was added to stop the reaction. The phosphorylated proteins were separated by SDS-PAGE. The gels were dried, scanned, and quantitated in a phosphorimager. Each kinase assay starting at transfection and ending with the determination of the protein kinase activity was repeated two to three times with similar results.
RESULTS

MKK6
Stimulates VDR Promoter Activity-To test directly the hypothesis that p38 kinase stimulates VDR expression, the mouse VDR promoter in a luciferase reporter vector (VDR-Luc) (37) was expressed transiently in human breast cancer MCF-7 cells with a constitutively active MKK6 (MKK6/E), an upstream activator of p38 kinase (45) , or an empty vector control. As a further control, a constitutively active MEK1 (MEK1/E), an ERK activator, was co-transfected with the VDR-Luc vector into MCF-7 cells. It was observed that MKK6/E expression stimulates the VDR-Luc promoter activity by 10-fold, whereas the transfection with MEK1 has no effect (Fig. 1A) . Because vitamin D 3 is known to induce its receptor, VDR, protein expression (53, 54), we examined whether the MKK6 activation is regulated by vitamin D 3 . Accordingly, MKK6/E-and VDR-Luctransfected cells were incubated with 0.1 M vitamin D 3 for 48 h prior to the luciferase assay. The results showed that the VDR promoter activation in MCF-7 cells is independent of vitamin D 3 . This is consistent with the lack of a potential VDRE sequence in the VDR promoter (37) .
Previous work has suggested that there are functional interactions between vitamin D 3 /VDR and estrogen signaling in breast cancer cells (55) . It is, therefore, important to determine whether the VDR promoter stimulation by the p38 activation is ER-dependent in breast cancer cells. Fig. 1B shows that p38 activation by MKK6/2E expression stimulates the VDR promoter 6-fold in ER-negative human breast cancer MDA-MB-468 (468) cells (56) . Activation of the ERK pathway by MEK1/E in these cells also increases the promoter activity by 4-fold, a phenomenon that was not seen in ER-positive MCF-7 cells. Similar to ER-positive MCF-7 cells, addition of vitamin D 3 does not alter the pattern of VDR promoter activation, despite the fact that the promoter activity was decreased in the vector-, MKK6/E-, and MEK1/E-transfected groups, probably as a result of nonspecific effects of vitamin D 3 . Taken together, these results demonstrate that MKK6 expression is able to stimulate the VDR promoter activity in human breast cancer cells, independently of ER status and the presence of vitamin D 3 .
MKK6 Increases VDR Expression, VDRE Binding, and Vitamin D 3 -induced Growth Inhibition in Human Breast Cancer
Cells-In order to establish activation of endogenous VDR by MKK6, recombinant adenoviruses encoding MKK6/E (35, 36) were applied to assess its effect on VDR expression and its biological activities. The infection efficiency in these two human breast cancer cells is more than 90%, and the results of Fig. 2A showed overexpression of the MKK6 protein following infection with the ad-MKK6 vector. After ad-MKK6 infection, total RNA was prepared and hybridized with 32 P-labeled VDR cDNA probe. Fig. 2B shows that there is an increase in the VDR mRNA induced by MKK6 in comparison with the vector control in both MCF-7 and 468 cell lines. The mRNA elevation correlates with an increased level of VDR protein assayed by Western blot analyses (Fig. 2C) . Importantly, ad-MKK6 does not increase ER protein expression (data not shown), indicating a specific effect on the steroid receptor VDR but not ER.
To determine whether the elevated VDR is active in binding to its specific sequence VDRE, EMSA was performed by incubation of the labeled specific VDRE-containing oligo (DR3, Santa Cruz Biotechnology) with the nuclear lysates of MCF-7 and 468 cells following ad-MKK6 infection. Ad-MKK6-infected cells showed more protein binding to the DR3 oligo, which was completely inhibited by pre-incubation with excess cold wildtype oligo (Fig. 3A) , indicating that the elevated VDR protein expression by the MKK6 is functionally active with regard to VDRE binding.
Because functional VDR is required for vitamin D 3 -induced growth inhibition in breast cancer cells (9, 10) , VDR activation by MKK6 is expected to increase the sensitivity of MCF-7 cells to vitamin D 3 -dependent growth inhibition. To directly test this possibility, MCF-7 cells were infected first with the control virus or ad-MKK6 for 5 h and were then fed with virus-free medium in the absence or presence of vitamin D 3 for 48 h. Cell proliferation was determined by [ 3 H]thymidine incorporation. Although MKK6 may activate additional target genes, under these conditions neither ad-MKK6 nor vitamin D 3 alone had any obvious inhibitory effect on DNA synthesis (Fig. 3B, 
MKK6 Stimulates VDR through the p38/JNK/c-Jun/AP-1
Pathways-MKK6 is known to specifically activate all isoforms of p38 (45, 57, 58) . Recent observations suggest that MKK6 can also stimulate JNK in various occasions (59, 60) . 2 Experiments were carried out to determine whether MKK6 signals to VDR via the p38 and/or the JNK pathways. MCF-7 cells were chosen for these analyses because the VDR promoter stimulation in these cells is more significant and is selectively responsive to the p38 activation by MKK6 but not to the ERK activation by MEK1 (Fig. 1A) . p38 activity was assessed by assay of transiently expressed FLAG-p38 together with MKK6/E or MEK1/E and was compared with the activities of transfected GST-tagged ERK and JNK. The kinase activities were determined by assessing the activity of the precipitates immunoprecipitated with anti-FLAG antibody or with GSH beads followed by addition of their respective substrates in vitro (MBP for ERK, GST-Jun for JNK, and GST-ATF2 for p38) as described previously (41, 49) . The MKK6/E was shown to strongly activate p38, whereas the ERK activity was stimulated only by the MEK1/E and not MKK6/E (Fig. 4A) . Of interest, MKK6 also increased the JNK activity, albeit by a moderate level. In support of the validity of the results with exogenously expressed MAPKs, infection with ad-MKK6 also stimulated endogenous p38 and JNK when these enzymes were purified with respective antibodies and assessed for their kinase activities (Fig. 4B) . These results suggest that MKK6 may activate VDR through both p38 and JNK kinases.
AP-1 is a major transcription factor, which consists of homodimers of the Jun family (c-Jun, JunD, and JunB) or heterodimers of a Jun family member with any of the Fos family members (c-Fos, FosB, Fra-1, and Fra-2) or other transcription factors such as ATF2, CREB, and NFAT. Because all three MAPK pathways (ERK, JNK, and p38) can activate AP-1 (61), experiments were performed next to examine whether AP-1 functions as an integrating module transmitting the p38 and JNK signals from MKK6 to VDR gene. AP-1 activity was determined by transient expression of an AP-1 luciferase promoter (a minimal c-fos promoter containing three additional AP-1 element repeats) (47) to assay for AP-1-driven gene expression, together with the active MKK6/E-expressing plasmid and various inhibitors of the p38 and JNK pathways. As shown in Fig. 5A , activation of p38 and JNK by MKK6 expression increased AP-1 activity by a mechanism requiring both p38 and JNK activities, because co-expression of either dominant negative p38 (p38/AF) or JNK (JNK/AF) substantially reduced AP-1 trans-activation. The role of p38 is further confirmed by decreased AP-1 activity in the presence of a chemical p38 inhibitor SB203580. In a similar manner (Fig. 5B) , the stimulation of VDR promoter by MKK6 is also inhibited by dominant negatives of either p38 (p38/AF, SB 203586) or JNK (JNK/AF), indicating a requirement of both the p38 and JNK pathways for the VDR activation. Together, these results suggest that the signaling from p38 and JNK activation is integrated at AP-1, which may contribute to the VDR trans-activation. Consistent with this conclusion, expression of a dominant active JNK kinase kinase MEKK1 also increases kinase activity of JNK and p38 (Fig. 4A ) and stimulates AP-1 reporter (Fig. 5C ) and VDR promoter activity (Fig. 5D) .
The above results suggest a potential role of AP-1 activity in the stimulation of VDR gene expression by p38 and JNK activation. To further confirm the involvement of AP-1 in VDR activation and analyze molecular mechanisms of the AP-1 activity, a mutant c-Jun, Tam67, was used in the co-transfection. Tam67 codes for c-Jun minus its activation domain, and its expression has been shown to quench AP-1 trans-activating activities (42-44) . Expression of Tam67 in MCF-7 cells inhibited the MKK6/E-induced but not basal AP-1 activity (Fig. 5A) .
Importantly, Tam67 also suppressed the MKK6/E-triggered VDR promoter activation (Fig. 5B) . These results suggest a potential involvement of c-Jun in AP-1 activation and further support the role of AP-1 activity in VDR stimulation.
To further confirm c-Jun involvement, the level of the major AP-1 components (c-Jun, c-Fos, and ATF-2) was determined at 24 and 48 h after infection with the ad-MKK6 by Western blot analysis. As shown in Fig. 6A , c-Jun was undetectable in MCF-7 cells in the control infection, which was in agreement with previous reports (62) . Ad-MKK6 significantly induced cJun protein level at 48 h, which correlated with the increase in phosphorylated c-Jun as detected with a specific antibody against phosphorylated c-Jun at Ser-63 (data not shown). Levels of ATF-2 were not altered by ad-MKK6, nor were the levels of c-Fos. To further establish the role of c-Jun in AP-1 activity, MCF-7 cells were stably transfected with the Tam67 construct and selected for G418 expression and expression of the truncated 29-kDa c-Jun protein as described (Fig. 6B) (44) . AP-1 binding activity to a synthesized AP-1 consensus sequence was determined by EMSA. Fig. 6C shows that the nuclear lysates from ad-MKK6-infected cells have higher AP-1 binding activity than in the vector-transfected MCF-7 cells (MCF/Vect). Binding specificity is suggested by the complete inhibition of protein binding by competing with 50-fold cold excess of wild-type oligo. In MCF-7 cells stably expressing the dominant negative c-Jun Tam67 (MCF/Tam), however, there was no increase in binding to the AP-1 sequence after the MKK6 infection. Similar to our results, an inhibition of nickel-induced AP-1 element binding by Tam67 in human bronchial epithelial cells recently was reported (63) . Supporting the role of c-Jun in AP-1 activity, c-Jun antibody decreased the AP-1 element binding to the control level. Surprisingly, although ATF2 is a major substrate of p38 (1, 2), anti-ATF2 had no effect on the retarded protein band (Fig. 6D) , indicating that p38 induction of AP-1 activity is ATF2-independent. Taken together, these data support the hypothesis that MKK6 activates VDR via a p38-and JNK-dependent c-Jun/AP-1 pathway.
The AP-1 Sequence on the VDR Promoter Mediates Stimulation by MKK6 -In the experiments described below we directly tested effects of AP-1 enhancer activation by site-directed mutagenesis of the VDR promoter to further confirm the role of AP-1 on VDR promoter activity. There is a single potential AP-1 consensus sequence in the VDR promoter between Ϫ377 and Ϫ370 (TGACACA) (Fig. 7A) , which differs by only one nucleotide from the consensus AP-1 site TGACTCA as found in the osteocalcin promoter (37) (the same sequence that was used as the probe for AP-1 binding in EMSA under "Materials and Methods"). The TGACACA sequence in the VDR promoter was mutated to TGCTACA, and the mutated promoter was cloned into a pGL2 basic luciferase vector to generate the M1 VDR luciferase reporter vector. A second mutant VDR reporter vector was made with double mutations at TGCTAGG to obtain the M2 VDR luciferase reporter (underline indicates mutated nucleotides). Site-directed mutagenesis was achieved using QuikChange™ site-directed mutagenesis kit as instructed in the user's manual and confirmed with enzyme digestion and DNA sequencing. The effect of stimulation by MKK6/E was then determined with transient transfections. Expression of c-Jun and c-Fos by transient transfection to generate high cellular levels of AP-1 activity was used as a positive control. As shown in Fig. 7B , stimulation of VDR promoter activity by p38 and JNK activation by MKK6/E was dramatically decreased when the AC was changed to CT (the M1 promoter) and was almost completely abolished when additional nucleotides, CA, were changed to GG (the M2 promoter, p Ͻ 0.05 for M2 promoter versus wild-type promoter). The specificity of these mutations is further confirmed by a similar decrease of the luciferase activity in both mutants in the presence of AP-1 expression caused by the transfection with c-Jun plus c-Fos plasmids. A similar mutation in the AP-1 consensus sequence of cyclin D1 promoter was found to block c-Jun-mediated transactivation (64). These results provide direct evidence that the AP-1 sequence in the VDR promoter is responsible for the increase in VDR expression stimulated by the p38 and JNK activities conferred by MKK6.
ARS Activates JNK/p38/AP-1 and Increases VDR ExpressionThe above results clearly have demonstrated that signaling from the p38 and JNK pathways conferred by MKK6 expression can be integrated at c-Jun/AP-1, leading to trans-activation of the VDR gene via the AP-1 consensus sequence on the VDR promoter in human breast cancer cells. Although expression of genetic materials is essential for establishing a specific signal transduction pathway to control a target gene expression, efforts also were made to confirm and extend these results without MKK6 transfection to further examine the physiological relevance of this observation. Arsenite, a well known p38 and JNK stimulator in many cell lines (49, (65) (66) (67) , was included here to investigate effects of activation of endogenous p38 and JNK on AP-1 activity and VDR expression in these human breast cancer cells. ARS in MCF-7 cells stimulated AP-1 reporter activity (Fig. 8A) , AP-1 DNA binding (not shown), and VDR promoter activity (Fig. 8B) . Following ARS treatment, cell lysates were collected, endogenous p38 and JNK were immunoprecipitated, and the kinase activities determined as described above (Fig. 4) . Treatment with ARS strongly activated MKK6 (data not shown) and endogenous p38 and JNK (Fig. 8C) . Most importantly, the same treatment also increased VDR protein expression (Fig. 8D) . Although additional pathways also may be activated by ARS, at least part of the VDR protein induction by ARS can be ascribed to activation of the p38/JNK/AP-1 pathway (Fig. 9) . These results, therefore, establish that activation of the endogenous stress pathways by a chemical stimulus ARS leads to AP-1 activation and to increased VDR protein expression. 
DISCUSSION
Our results demonstrate that the stress-activated protein kinases p38 and JNK trans-activate VDR through c-Jun-dependent AP-1 and sensitize human breast cancer cells to vitamin D 3 -dependent growth inhibition. This conclusion is based on the following observations. 1) MKK6 expression stimulated the exogenous and endogenous p38 and JNK pathways, which elevated both AP-1 trans-activation and VDR promoter activities. 2) Both the p38 and JNK activities are required for the AP-1 and VDR activations as shown by the transfection of dominant negative JNK and p38 genes and by the specific chemical p38 inhibitor SB203580.
3) The central role of c-Jun/ AP-1 in this stimulation was shown by the selective c-Jun activation following stimulation of endogenous p38 and JNK by ad-MKK6, by the inhibitory effect of the mutant c-Jun (Tam67) on the induced AP-1 and VDR activations, and by the inhibitory effect of site-directed mutagenesis of the AP-1 element in the VDR promoter. 4) The biological significance of the VDR activation by p38 and JNK kinases was shown by the sensitization of MCF-7 cells to vitamin D 3 -mediated growth inhibition after infection with ad-MKK6. 5) The signaling connection between these stress pathways and VDR activation was further supported independently by treatment of the cells with the stress stimulator ARS. This work thus shows a previously unknown connection between the p38 and JNK MAPK pathways and the steroid hormone receptor VDR signaling through activation of the transcription factor c-Jun/AP-1.
The ERK or JNK MAPK pathway has been shown to interact with and phosphorylate ER (17, 20, 22, 68) and PR (18, 19, 23) at multiple levels in different systems. Our results show that VDR is stimulated transcriptionally by the p38/JNK pathway stimulation of AP-1. To our knowledge, this is the first report to show regulation of a steroid hormone receptor expression by MAPK pathways. In MCF-7 cells, the signaling connection between p38/JNK to VDR appears to be specific because activation of the ERK pathway by the constitutively active MEK did not stimulate VDR promoter (Fig. 1A) . Also, the stimulation of the p38 and JNK pathways by ad-MKK6 increased levels of VDR but not ER protein expression (Fig. 2C and data not shown). The p38/JNK signaling specificity in MCF-7 cells is further demonstrated by the observation that the VDR promoter stimulation by MKK6 expression is vitamin D 3 -and ER-independent, in contrast to observations in some other systems (53, 69) . The cooperative role of p38 and JNK in stimulation of VDR is suggested by the fact that both MKK6 and ARS stimulate both kinases, that inhibition of one of them is sufficient to block the AP-1/VDR stimulation, and that activation of p38/JNK by an independent molecule (MEKK1) also increases AP-1 and VDR activity (Fig. 4 and Fig. 5, C and D) . Because VDR can bind to the VDRE in a manner independent of its ligand vitamin D 3 (70) , these results suggest that the p38/JNK stress pathways may regulate VDR-dependent target gene expression through VDR trans-activation without a requirement for the binding of vitamin D 3 .
Although our data are consistent with the notion that increased VDR activity is caused by transcriptional activation by p38 and JNK activities through the AP-1 consensus sequence, additional mechanisms such as VDR phosphorylations and interactions with molecules of the MKK6/p38/JNK/c-Jun pathway may also be involved in the increased VDR binding and the enhanced vitamin D 3 -dependent growth inhibition. It has been shown, for example, that VDR can be phosphorylated by casein kinase II at Ser-208, resulting in an increased transcriptional activity; albeit this remains to be confirmed (71, 72) . Moreover, transcription factor activity of the VDR protein may be regulated by the phosphorylation of its partner RXR␣ at Ser-260 by the Ras/ERK pathway, leading to a decrease in VDR transactivation activity and vitamin D 3 -dependent growth inhibition (29) . In addition, VDR can co-associate with other transcription factors including Smad3 (73, 74) and transcription factor IIB (TFIIB) (7) . The in vitro direct binding of VDR to c-Jun but not c-Fos was also described recently (75) . It is therefore possible that in addition to transcriptional regulation, potential direct interactions between VDR and the MKK6/p38/JNK/c-Jun pathway also may contribute to increased VDR activity and subsequent potentiation of vitamin D 3 -induced growth inhibition.
The VDR is generally expressed at relatively low levels in vivo, and consequently regulation of VDR levels is an important approach for the regulation of vitamin D 3 -responses in target cells (7) . Indeed, efforts have been made to regulate VDR expression using chemical stimuli including forskolin (37) and phorbol 12-myristate 13-acetate (30) . The outcome of these investigations, however, is limited by nonspecific properties of these reagents. Elucidation of the signal transduction pathways that control VDR expression thus has important implications in the regulation of vitamin D 3 activity. VDR up-regulation by the activation of endogenous p38 and JNK pathways by both MKK6 expression and ARS treatment indicates the feasibility of this regulation. Because functional VDR has been demonstrated to be required for vitamin D 3 -induced growth inhibition in breast cancer and other malignant cell lines (10 -14) , VDR stimulation by the p38/JNK stress pathways may aid in developing new strategies to improve therapeutic efficacy of vitamin D 3 and overcome its resistance in tumor cells.
